-Issues related to FDA review of active ingredients in over-the-counter products
-Issues related to Generally Recognized as Safe (GRAS) and Additive Ingredients Regulation (no bill) -Issues related to New Approach Methodologies (NAMs) non-animal technologies used to evaluate drug safety and efficacy
-Issues Related to the Review of the US-Mexico-Canada Trade Agreement (No Bill) -Section 232 Pharmaceuticals Trade Investigation -Section 232 Semiconductors Trade Investigation -Section 232 Softwood Lumber Trade Investigation -Section 232 Medical Devices/PPE Trade Investigation -IEEPA Reciprocal Tariffs -Section 232 Industrial Machinery Trade Investigation -Section 122 Balance of Payment Tariffs -Section 232 Steel/Aluminum Trade Investigation -Section 301 Excess Capacity/Forced Labor Trade Investigation -Issues related to counterfeit products/illicit trade
-Issues Related to Product Safety and Quality Assurance (No Bill) -FDA Menstrual Products Guidance
-Issues related to updating the Toxic Substances Control Act (No Bill) -Implementation of Cybersecurity Reporting Law
-Issues related to sustainability -H.R.7502-Pro Recycled Materials Attribution Act (RMAA) -H.R. 2269/S. 1092 - Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act
-OECD Digital Tax Project (Global Minimum Tax Implementation) -Implementation of H.R. 1 - One Big Beautiful Bill Act (Corporate/International Provisions) -Ongoing Negotiations of US Bilateral Tax Treaties -H.R. 1219 - Oral Health Products Inclusion Act
-Mexico Foreign Direct Investment Policies